Original Article
Split Viewer
Blood Res 2023; 58(4):
Published online December 31, 2023
https://doi.org/10.5045/br.2023.2023206
© The Korean Society of Hematology
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
Correspondence to : Seok Jin Kim, M.D., Ph.D.
Deok-Hwan Yang, M.D., Ph.D.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul 06351, Korea (S.J.K.)
Department of Hematology-Oncology, Chonnam National University Medical School and Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun 58128, Korea (D.H.Y.)
E-mail: S.J.K., kstwoh@skku.edu
D.H.Y., drydh1685@hotmail.com
*This study was supported by Takeda Pharmaceuticals.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.
Methods
This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.
Results
A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P=0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).
Conclusion
The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
Graphical Abstract
Keywords: Brentuximab vedotin, CD30, Lymphoma, Outcome
PDF
Standard view
Export citation
Share Article
Original Article
Blood Res 2023; 58(4): 194-200
Published online December 31, 2023 https://doi.org/10.5045/br.2023.2023206
Copyright © The Korean Society of Hematology.
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
Seok Jin Kim1, Young Rok Do2, Ho-Sup Lee3, Won-Sik Lee4, Jee Hyun Kong5,6, Jae-Yong Kwak7, Hyeon-Seok Eom8, Joon Ho Moon9, Jun Ho Yi10, Jeong-Ok Lee11, Jae-Cheol Jo12, Deok-Hwan Yang13
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Department of Internal Medicine, 2Dongsan Medical Center, Daegu, 3Kosin University Gospel Hospital, 4Inje University Busan Paik Hospital, Busan, 5Division of Hematology-Oncology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, 6Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, 7Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, 8Hematology-Oncology Clinic, National Cancer Center, Goyang, Department of Internal Medicine, 9Kyungpook National University Hospital, Daegu, 10Chung-Ang University Hospital, Seoul, 11Seoul National University Bundang Hospital, Seongnam, Department of Hematology and Oncology, 12Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 13Chonnam National University Medical School and Hwasun Hospital, Hwasun, Korea
Correspondence to:Seok Jin Kim, M.D., Ph.D.
Deok-Hwan Yang, M.D., Ph.D.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul 06351, Korea (S.J.K.)
Department of Hematology-Oncology, Chonnam National University Medical School and Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun 58128, Korea (D.H.Y.)
E-mail: S.J.K., kstwoh@skku.edu
D.H.Y., drydh1685@hotmail.com
*This study was supported by Takeda Pharmaceuticals.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.
Methods
This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.
Results
A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P=0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).
Conclusion
The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
Keywords: Brentuximab vedotin, CD30, Lymphoma, Outcome
Fig 1.
Download
Fig 2.
Download
Fig 3.
Download
-
Table 1 . Characteristics of patients..
Total (N=85) Hodgkin lymphoma (N=48) Anaplastic large cell lymphoma (N=25) Mycosis fungoides (N=12) Median age at BV (range, yr) 48 (18–84) 34 (19–83) 55 (18–84) 62 (32–84) Age at BV treatment Age ≤60 years 56 (66) 37 (77) 14 (56) 5 (42) Age >60 years 29 (34) 11 (23) 11 (44) 7 (58) Sex Male 51 (60) 34 (71) 13 (52) 4 (33) Female 34 (40) 14 (29) 12 (48) 8 (67) ECOG PS prior to BV 0 61 (72) 32 (67) 19 (76) 10 (83) 1 15 (18) 11 (23) 2 (8) 2 (17) 2 9 (10) 5 (10) 4 (16) 0 (0) Stage at diagnosis I/II 8/33 (48) 4/23 (56) 3/4 (28) 1/6 (58) III/IV 18/26 (52) 6/15 (44) 7/11 (72) 5/0 (42) Stage prior to BV I/II 4/35 (46) 2/22 (50) 1/7 (28) 1/6 (58) III/IV 18/28 (54) 9/15 (50) 5/12 (72) 4/1 (42) Mediastinum Not involved 50 (59) 15 (31) 23 (92) 12 (100) Involved 35 (41) 33 (69) 2 (8) 0 (0) IPS at diagnosis Low (0–3 points) 35 (73) High (4–7 points) 13 (27) IPS prior to BV Low (0–3 points) 37 (77) High (4–7 points) 11 (23) Refractory to 1st-line Tx No 46 (54) 27 (56) 14 (56) 5 (42) Yes 39 (46) 21 (44) 11 (44) 7 (58) Previous RT before BV Not done 73 (86) 38 (79) 25 (100) 10 (83) Done 12 (14) 10 (81) 0 (0) 2 (17) Previous ASCT before BV Not done 70 (82) 36 (75) 22 (88) 12 (100) Done 15 (18) 12 (25) 3 (12) 0 (0) Previous Tx before BV One line 32 (38) 8 (17) 17 (68) 7 (58) Two lines 33 (39) 23 (48) 7 (28) 3 (25) More than two lines 20 (23) 17 (35) 1 (4) 2 (17) Time between Dx and BV <12 months 26 (30) 10 (21) 12 (48) 4 (33) 12–36 months 32 (38) 21 (44) 6 (24) 5 (42) >36 months 27 (32) 17 (35) 7 (28) 3 (25) Abbreviations: ASCT, autologous stem cell transplantation; BV, brentuximab vedotin; Dx, diagnosis; ECOG, Eastern Cooperative Oncology Group; IPS, International Prognostic Score; PS, performance status..
-
Table 2 . Safety profile..
Patients (N=85) All grades G3 G4 Anemia 7 3 0 Anorexia 7 0 0 Constipation 8 3 0 Diarrhea 5 2 1 Fatigue 10 0 0 Febrile neutropenia 11 5 0 Fever 11 4 0 Insomnia 3 0 0 Nausea 10 0 0 Neutropenia 13 4 1 Peripheral neuropathy 22 5 2 Pneumonia 4 2 0 Skin rash 4 0 0 Thrombocytopenia 12 5 0 Vomiting 2 0 0
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Brentuximab vedotin: clinical updates and practical guidance
Jun Ho Yi, Seok Jin Kim, and Won Seog Kim
Blood Res 2017; 52(4): 243-253 -
Peripheral T-cell lymphoma, NOS in bone marrow and heart
Hye Won Lee and Ja Young Lee
Blood Res 2024; 59(): -
Genomic technologies for detecting structural variations in hematologic malignancies
Mi‑Ae Jang
Blood Res 2024; 59():
